Erlotinib-induced skin manifestations.
Motoki
Tomoteru
T
Mitsuishi
Tsuyoshi
T
Kawana
Seiji
S
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects*
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors